|
| Press Releases |
|
 |
|
| Monday, September 14, 2015 |
|
|
Eisai to Present Latest Clinical Data on Lenvima (Lenvatinib) and Halaven (Eribulin) at European Cancer Congress |
Eisai Co., Ltd. announced today that a series of abstracts highlighting the latest clinical data on Lenvima and Halaven will be presented during the European Cancer Congress (ECC) 2015, taking place in Vienna, Austria, from September 25 to 29.
more info >> |
|
| Thursday, September 10, 2015 |
|
|
Drugs for Neglected Diseases initiative and Eisai to Test Drug Candidate for Eumycetoma Patients suffering from virtually no R&D for this neglected disease |
| The Drugs for Neglected Diseases initiative (DNDi) and the Japanese pharmaceutical company Eisai Co., Ltd. have signed an agreement to proceed with the clinical development of Eisai's anti-fungal drug fosravuconazole for the potential new treatment of eumycetoma, a fungal form of mycetoma, one of the world's most neglected diseases. more info >> |
|
| Friday, July 31, 2015 |
|
|
Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and Pegph20 in Advanced Breast Cancer |
Eisai Co., Ltd. and Halozyme Therapeutics, Inc. announced today that they have signed a clinical collaboration agreement to evaluate Eisai's
anticancer agent eribulin mesylate in combination with Halozyme's investigational new drug PEGPH20 in first line HER2-negative advanced breast cancer. more info >> |
|
|
Continuation of "Policy for Protection of The Company's Corporate Value and Common Interests of Shareholders (Shareholder Rights Plan)" |
| The Board of Directors of Eisai Co., Ltd. passed a resolution for the continuation of the "Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders", which was proposed by the Independent Committee of Outside Directors at its meeting held today. more info >> |
|
| Wednesday, July 29, 2015 |
|
|
Eisai's In-House Developed Novel Anticancer Agent Lenvima Receives Breakthrough Therapy Designation From U.S. Fda for Renal Cell Carcinoma |
| Eisai Co., Ltd. announced today its U.S. subsidiary Eisai Inc. has received a Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its in-house developed novel anticancer agent Lenvima for the potential indication of advanced and/or metastatic renal cell carcinoma. more info >> |
|
| Friday, June 26, 2015 |
|
|
Eisai to Launch New Fine Granule Formulation of Tachyarrhythmia Treatment Tambocor Suitable for Pediatric Patients in Japan |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it will launch Tambocor Fine Granules 10%, a new formulation of anti-arrhythmic agent Tambocor (flecainide acetate), on June 29 in Japan. more info >> |
|
| Monday, June 22, 2015 |
|
|
U.S. FDA Approves Eisai's Antiepileptic Agent Fycompa as Adjunctive Treatment For Primary Generalized Tonic-Clonic Seizures |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an indication expansion regarding the use of its in-house developed antiepileptic agent Fycompa (perampanel hydrate) as an adjunctive treatment of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy 12 years of age and older. more info >> |
|
| Monday, June 1, 2015 |
|
|
Eisai Receives European Commission Approval of Anticancer Agent Lenvima for Treatment of Advanced Thyroid Cancer Refractory to Radioactive Iodine |
| Eisai Co., Ltd. announced today that its U.K. subsidiary Eisai Europe Ltd. has received approval from the European Commission (EC) for anticancer agent Lenvima (lenvatinib mesylate) in the treatment of adult patients with progressive, locally advanced or metastatic differentiated (papillary, follicular, Hurthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). more info >> |
|
| Friday, May 29, 2015 |
|
|
AbbVie and Eisai Clear All-Case Surveillance Condition for Approval of HUMIRA, a Fully Human Anti-TNF-alpha Monoclonal Antibody, in the Treatment of Ankylosing Spondylitis |
| AbbVie GK and Eisai Co., Ltd. announced today that they have received notification from Japan's Ministry of Health, Labour and Welfare (MHLW) to the effect that the "all-case surveillance" special drug use-results survey condition required for approval of HUMIRA Pre-filled Syringe 40 mg / 0.8 mL, a fully human anti-TNF-alpha monoclonal antibody formulation, has been lifted for use in patients with ankylosing spondylitis. more info >> |
|
| Wednesday, May 27, 2015 |
|
|
Eisai Submits New Drug Application for Mecobalamin Ultra-High Dose Preparation as Treatment for Amyotrophic Lateral Sclerosis in Japan |
| Eisai Co., Ltd. announced today that it has submitted a new drug application for mecobalamin (development code: E0302) as a treatment for amyotrophic lateral sclerosis (ALS) in Japan. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Formerra Achieves ISCC PLUS Certification Across U.S. Warehouses, Enhancing Sustainable Material Distribution
May 8, 2024 22:00 HKT/SGT
|
|
|
Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study
May 8, 2024 21:10 HKT/SGT
|
|
|
Build4Asia and Retail Asia Conference & Expo Kick Off Today 
May 8, 2024 21:10 HKT/SGT
|
|
|
Indonesian BFSI IT Summit: Revolutionizing Finance Through Digital Transformation
May 8, 2024 17:12 HKT/SGT
|
|
|
Crypto Oasis Thrives: UAE Blockchain Ecosystem sees Exponential Growth with 2,040 Active Organizations in Q1 2024
May 8, 2024 17:00 HKT/SGT
|
|
|
Datacloud APAC: Charting the Course for APAC's Cloud Future
May 8, 2024 16:20 HKT/SGT
|
|
|
Mitsubishi Heavy Industries Increases Dividends on Back of Historically High FY2023 Results, Releases FY2024 Guidance
May 8, 2024 14:27 JST
|
|
|
Capital.com's Client Trading Volumes Surpass USD1 trillion in 2023
May 8, 2024 12:00 HKT/SGT
|
|
|
Spritzer EcoPark Taiping Brightens up the Sky with an Enchanting Aurora Light Show at Food, Arts and Music Carnival
May 8, 2024 11:32 HKT/SGT
|
|
|
Rome becomes the first European city to offer open loop transit payments to JCB Cardmembers
May 8, 2024 12:00 JST
|
|
|
NEC X Invests in Public Safety Startup Multitude Insights, Scaling AI-Powered Collaboration and Information Sharing for Law Enforcement
May 8, 2024 10:24 JST
|
|
|
Avance Clinical Expands Further into APAC with New Clinical Operations in South Korea
May 8, 2024 09:00 HKT/SGT
|
|
|
Zhang Zhehan's Directorial Debut Documentary 'August' Premiered Online, Receiving Rave Reviews From Audiences
May 8, 2024 09:00 HKT/SGT
|
|
|
ServiceNow and Fujitsu announce strategic commitment to launch innovative cross-industry solutions
May 8, 2024 8:52 JST
|
|
|
CropLife Asia announces new Office Bearers for 2024
May 8, 2024 01:50 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
